The DOI matches its Crossref record.
Early Detection of Sporadic Pancreatic Cancer: Summative Review
Open accessAbstract
Pancreatic cancer (PC) is estimated to become the second leading cause of cancer death in the United States by 2020. Early detection is the key to improving survival in PC. Addressing this urgent need, the Kenner Family Research Fund conducted the inaugural Early Detection of Sporadic Pancreatic Cancer Summit Conference in 2014 in conjunction with the 45th Anniversary Meeting of the American Pancreatic Association and Japan Pancreas Society. This seminal convening of international representatives from science, practice, and clinical research was designed to facilitate challenging interdisciplinary conversations to generate innovative ideas leading to the creation of a defined collaborative strategic pathway for the future of the field. An in-depth summary of current efforts in the field, analysis of gaps in specific areas of expertise, and challenges that exist in early detection is presented within distinct areas of inquiry: Case for Early Detection: Definitions, Detection, Survival, and Challenges; Biomarkers for Early Detection; Imaging; and Collaborative Studies. In addition, an overview of efforts in familial PC is presented in an addendum to this article. It is clear from the summit deliberations that only strategically designed collaboration among investigators, institutions, and funders will lead to significant progress in early detection of sporadic PC.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Figures
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“If the stage distribution could be reversed, to 50% localized and 10% metastatic, survival would be more than doubled without any additional improvements in therapy.3”
From Artificial Intelligence and Early Detection of Pancreatic Cancer: 2020 Summative Review (2021) · cites this paper as [3]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“and the currently used blood-based biomarker, CA 19-9, accurately predicts only 65% of those with early disease when surgical treatment is a viable option.3,167”
From Artificial Intelligence and Early Detection of Pancreatic Cancer: 2020 Summative Review (2021) · cites this paper as [3]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“However, screening in the asymptomatic population is not recommended due to the economic burden and the relatively low incidence of PC in the general population 21,22.”
From Artificial intelligence in pancreatic cancer (2022) · cites this paper as [22]
The cited source says what the claim attributes to it.
In the citing paper
“Early symptoms of the disease are mostly nonspecific.”
From Artificial Intelligence and Early Detection of Pancreatic Cancer: 2020 Summative Review (2021) · cites this paper as [2]
The cited source says what the claim attributes to it.
In the citing paper
“Furthermore, the size of the lesion at the time of surgery is a predictor of long-term survival.3,166,167”
From Artificial Intelligence and Early Detection of Pancreatic Cancer: 2020 Summative Review (2021) · cites this paper as [3]
The cited source says what the claim attributes to it.
In the citing paper
“Several studies have shown that early detection of PDAC improves outcome.”
From Artificial Intelligence and Early Detection of Pancreatic Cancer: 2020 Summative Review (2021) · cites this paper as [3]
The cited source says what the claim attributes to it.
In the citing paper
“This result is based on the findings that surgery is the only therapy to date associated with a durable long-term outcome.”
From Artificial Intelligence and Early Detection of Pancreatic Cancer: 2020 Summative Review (2021) · cites this paper as [3]
In the citing paper
“a multitude of circulating tumor-derived analytes (proteins, autoantibodies, metabolites, DNA, non-coding RNAs and extracellular vesicles, among others) have been assessed in the context of PDAC early detection39–41.”
From Pancreatic cancer: Advances and challenges (2023) · cites this paper as [39]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Still being checked.
Research works printed but not linked: 1
- References are available online at: http://links.lww.com/MPA/A374.
Cited by
Sorted by citations
Kleeff, J., Korc, M., Apte, M., La Vecchia, C., Johnson, C. D., Biankin, A. V., Neale, R. E., Tempero, M., Tuveson, D. A., Hruban, R. H., et al. (2016) · Nature Reviews Disease Primers · doi:10.1038/nrdp.2016.22 · Cited by 1,982
New Technologies for Analysis of Extracellular Vesicles
Shao, H., Im, H., Castro, C. M., Breakefield, X. O., Weissleder, R., & Lee, H. (2018) · Chemical Reviews · doi:10.1021/acs.chemrev.7b00534 · Cited by 1,697
Pancreatic cancer: Advances and challenges
Halbrook, C. J., Lyssiotis, C. A., Pasca di Magliano, M., & Maitra, A. (2023) · Cell · doi:10.1016/j.cell.2023.02.014 · Cited by 1,321
Self-citationLin, J. S., Bowles, E. J. A., Williams, S. B., & Morrison, C. C. (2017) · JAMA · doi:10.1001/jama.2017.0562 · Cited by 1,082
ACG Clinical Guideline: Diagnosis and Management of Pancreatic Cysts
Elta, G. H., Enestvedt, B. K., Sauer, B. G., & Lennon, A. M. (2018) · The American Journal of Gastroenterology · doi:10.1038/ajg.2018.14 · Cited by 734
Metadata
- Authors
- Chari, S. T., Kelly, K., Hollingsworth, M. A., Thayer, S. P., Ahlquist, D. A., Andersen, D. K., Batra, S. K., Brentnall, T. A., Canto, M., Cleeter, D. F., Firpo, M. A., Gambhir, S. S., Go, V. L. W., Hines, O. J., Kenner, B. J., Klimstra, D. S., Lerch, M. M., Levy, M. J., Maitra, A., Mulvihill, S. J., Petersen, G. M., Rhim, A. D., Simeone, D. M., Srivastava, S., Tanaka, M., Vinik, A. I., & Wong, D.
- Affiliations
- Mayo Clinic (US)
- Eastern Virginia Medical School (US)
- University of California, Los Angeles (US)
- National Institutes of Health (US)
- The University of Texas MD Anderson Cancer Center (US)
- University of Washington (US)
- Corresponding author
- Chari, Suresh T.
- Ahlquist, David A.
- Canto, Marcia
- Klimstra, David S.
- Tanaka, Masao
- ORCID
- Chari, Suresh T.
- Hollingsworth, Michael A.
- Thayer, Sarah P.
- Ahlquist, David A.
- Andersen, Dana K.
- Batra, Surinder K.
- Brentnall, Teresa A.
- Canto, Marcia
- Firpo, Matthew A.
- Gambhir, Sanjiv Sam
- Hines, O. Joe
- Kenner, Barbara J.
- Klimstra, David S.
- Lerch, Markus M.
- Levy, Michael J.
- Maitra, Anirban
- Mulvihill, Sean J.
- Petersen, Gloria M.
- Rhim, Andrew D.
- Simeone, Diane M.
- Srivastava, Sudhir
- Tanaka, Masao
- Vinik, Aaron I.
- Venue
- Pancreas
- Published
- 2015-07
- Volume
- 44
- Issue
- 5
- Pages
- 693-712
- ISSN
- 0885-3177 (ISSN-L)
- PMC
- PMC4467589
- OpenAlex
- W2064141899
- Cited by
- 295
- References
- 0
- Citations by year
- 2026: 13 · 2025: 10 · 2024: 24 · 2023: 20 · 2022: 34 · 2021: 35 · 2020: 28 · 2019: 30 · 2018: 30 · 2017: 31 · 2016: 30 · 2015: 8
- FWCI
- 14.41
- Type
- journal article
- Language
- en
- Open access
- hybrid
- doi.org
- Licence
- cc-by-nc-nd
- Locations
- Pancreas (publishedVersion, cc-by-nc-nd)
- PubMed Central (publishedVersion, cc-by-nc-nd)
- PubMed (publishedVersion)
- eScholarship (California Digital Library) (submittedVersion)
- Funders
- National Cancer Institute (P50CA102701, R01CA168712, R01CA177857)
- Topics
- Health Sciences › Medicine › Oncology › Pancreatic and Hepatic Oncology Research
- Health Sciences › Medicine › Surgery › Pancreatitis Pathology and Treatment
- Health Sciences › Medicine › Oncology › Global Cancer Incidence and Screening
- Keywords
- pancreatic cancer, early detection, biomarkers, pancreatic imaging, familial pancreatic cancer, cancer survival, interdisciplinary collaboration, research gaps
- MeSH terms
- Biopsy, Congresses as Topic, Cooperative Behavior, Diagnostic Imaging, Diffusion of Innovation, Humans, International Cooperation, Pancreatic Neoplasms, Predictive Value of Tests, Prognosis, Biomarkers, Tumor, Survival Analysis, Carcinoma, Pancreatic Ductal, Molecular Diagnostic Techniques, Interdisciplinary Communication, Biomedical Research, Early Detection of Cancer
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
